

YOUR SMILE. OUR VISION.



Long successful operating history – founded in 1972 and listed on ASX in 1985 and Australia's largest dental manufacturer



SDI conducts research and development of specialist dentist materials undertaking the development, manufacturing and marketing of dental restorative materials



SDI sells to 100+ countries on all continents and with sales teams and distribution in Australia, Brazil, Europe and North America



YOUR **OUR** SMILE.**VISION.**

GLOBAL HEALTH CHALLENGE IN DENTISTRY

- Dental caries is a major public health problem globally, the most widespread noncommunicable disease
 - Dental caries consumed 5-10% of healthcare budgets in industrialised countries. A main reason for hospitalisation of children in some high-income countries
- Almost half of the world's population is affected by dental caries, making it the most prevalent of all health conditions
 - Severe dental caries often causes pain and infection, which may result in tooth extraction
 - Severe dental caries affects general health and well-being
 - During Covid-19 lockdowns, most countries allowed dental practices to treat dental emergency situations dental offices were classified as "permitted workplaces" during the recent Victorian lockdown.
 - "Going to the dentist for check-ups every six–12 months helps to prevent dental problems or find them early. If you notice any signs of a dental problem, visit your dentist to avoid any problems becoming worse."

Source: World Health Organisation, WHO Technical Information Note, October 2017; Australian Dental Association Victorian Branch



YOUR **OUR** SMILE. **VISION.**





ADDRESSING THE PROBLEM WITH INNOVATION

- Riva Star, a silver diamine fluoride or SDF, assists with stopping decay
- Riva restoratives ("fillings") and cements release fluoride and calcium to the tooth, making teeth stronger and
- All research and development is focused on developing stronger products for healthier teeth







PRODUCT CATEGORIES








PRODUCT MIX

- Significant product shift as a result of strategic shift and redirected research and development
- Contemporary products (Aesthetics and Whitening) have moved from 43% of sales to 73% of sales with ~10% CAGR in revenue over the last 8 years
- Amalgam decline reflects shifting consumer preferences and is expected continue to its trend in the coming years

Product Sales \$m






CATEGORY OVERVIEW

MOMENTUM IMPACTED BY COVID-19 WITH PRODUCT MIX CONTINUING TO DRIVE GROSS MARGIN

- Government restrictions impacted demand in all product groups, with dentists limited to emergency procedures
- Record Sales momentum in 1H20 impacted by global pandemic in 2H20, a traditionally the stronger half for the business
- Gross Margin improvement due to favourable product mix shift
 - Aesthetics (45.9% of sales) showed the smallest decline, down 9.1% (down 12.2% in local currency)
 - Whitening (26.9% of sales) and Equipment (7.6% of sales) down 15.4% and 14.9% (18.1% and 16.1% in local currency)
 - Amalgam (19.6% of sales) down 27.2% (down 29.7% in local currency)







GEOGRAPHIES


North America \$14.6m (23.9%) Europe \$23.7m (14.0%)

> Middle East/Africa \$6.9m (20.7%)

APAC \$14.2m (3.7%)


South America \$8.0m (14.3%)






FY20 SUMMARY

GROWTH MOMENTUM IMPACTED BY COVID-19 IN 2H20






Momentum slowed in 2H20, with dentists limited to emergency procedures

Gross margin up to 64.8%, with favourable product mix





FY19

■ H2 (\$m)

FY20

Management reacted promptly to changing conditions,
Directors and management salaries reduced by 40%

FY18

■ H1 (\$m)

FY17

- Costs carefully managed with YoY OPEX down 8.2%
- Devaluation of Brazilian Real (down 33% in 2H20) resulted in \$1.4m currency loss; Brazilian strategic review completed
- Despite challenging operating conditions, profitable in 2H

TRADING UPDATE

STRONG START TO THE FINANCIAL YEAR

- Strong first quarter in most regions (local currency)
 - Australia Domestic up 28%
 - North America up 15%
 - Brazil up 37%
 - Europe (ex-UK) up 25% UK down 80%

 - Australian Direct Exports down 22% Total sales down 1%
- Operating Expenses down 20% (down 12% excluding Government assistance)
- Gross Product Margins down 1%





STRATEGY & OUTLOOK

CLEAR STRATEGY AND POSITIVE OUTLOOK

STRATEGY

- 45% SKUs reduction expected to drive further efficiencies
- On-going investment in R&D with the release 1-2 products per year
- Pola Light USA and Australian launches performing very well
- Amalgam replacement product on schedule for release in 2023

OUTLOOK

- Strong start to the financial year, despite little contribution from the UK
- Operating expenses continue to be managed and gross margins to be maintained
- Continued product mix shift with growth tracking as expected in Aesthetic and Whitening, and continued decline in Amalgam products
- Inventory levels expected to be at normal levels by December 2020
- No debt by December 2020





Disclaimer

This Presentation contains summary information about SDI Limited (SDI) and its subsidiaries and their activities. The information in this Presentation does not purport to be complete. It should be read in conjunction with SDI's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

The information contained in this Presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek independent professional advice appropriate to their jurisdiction and circumstances.

To the extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by SDI, any of its related bodies corporate or its Directors, officers, employees, professional advisors and agents (Related Parties). No representation or warranty, express or implied, is made by any person, including SDI and its Related Parties, as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this Presentation.

An investment in SDI securities is subject to investment and other known and unknown risks, some of which are beyond the control of SDI or its Directors. SDI does not guarantee any particular rate of return or the performance of SDI securities.

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of SDI and associated entities of SDI and certain plans and objectives of the management of SDI. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of SDI to be materially different from the results or performance expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding SDI's present and future business strategies and the political, regulatory and economic environment in which SDI will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved.

Forward-looking statements speak only as at the date of this Presentation and to the full extent permitted by law, SDI and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this Presentation (including, but not limited to, any assumptions or expectations set out in this Presentation).

Statutory profit is prepared in accordance with the Corporations Act 2001 and the Australian Accounting Standards, which comply with the International Financial Reporting Standards (IFRS). Underlying profit is categorised as non-IFRS financial information and therefore has been presented in compliance with Australian Securities and Investments Commission Regulatory Guide 230 – Disclosing non-IFRS information, issued in December 2011.

All figures in this Presentation are A\$ unless stated otherwise and all market shares are estimates only. A number of figures, amounts, percentages, estimates, calculations of value and fractions are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this Presentation.

